TL;DR
Get health and wellness essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
In a first-person report published by Being Patient on October 6, 2026, patient advocate Ron Carr describes three health notifications that changed how he viewed Alzheimer’s risk and prevention. The supplied report details two: a genetic test showing two APOE4 copies and a coronary artery calcium scan showing significant plaque; it does not include the third notification or the article’s full ending.
Ron Carr’s account, published by Being Patient on October 6, 2026, describes how an APOE4 genetic test result and a coronary artery calcium scan changed his understanding of Alzheimer’s risk and heart health. The source material provided for this report details two of the three notifications named in the article’s headline; it does not provide the third notification or the full article ending.
Carr, a retired local government executive and patient advocate, writes that a genetic test two years earlier showed he carries two copies of APOE4, a genetic risk factor associated with late-onset Alzheimer’s disease. He says the result initially made ordinary lapses, such as forgetting a name or misplacing keys, feel like possible signs of illness. He describes responding by extensively researching Alzheimer’s and repeatedly changing his diet, exercise routine, supplements and sleep medication.
Over time, Carr says he came to understand that APOE4 is a risk factor, not a diagnosis. He writes that learning about risks he could potentially influence made him feel less helpless, while his genes themselves had not changed. His account does not say that lifestyle changes prevent Alzheimer’s or quantify any effect they had on his personal risk.
The second notification followed a coronary artery calcium scan, which Carr says he underwent because of his APOE4 status. Although he felt healthy and had cholesterol levels his physician had previously considered acceptable, the scan showed significant calcified plaque, mostly in his left anterior descending artery. Carr says his clinician then pursued lower LDL cholesterol and ApoB levels and advised him to avoid saturated fat. He reports that follow-up testing showed no evidence of structural heart damage.
Genetic Risk Led to Heart Screening
Carr’s story illustrates how a test result can prompt further conversations about health risks beyond the condition most associated with that result. In his case, he says clinicians discussed APOE4’s role in lipid transport and arranged a heart scan; the scan identified plaque that he says had not caused noticeable symptoms. That sequence is his personal experience, not evidence that every person with APOE4 should have the same test or treatment.
The account also highlights the difference between a risk marker and a diagnosis. Carr describes the anxiety that followed his genetic result and the change in outlook that came with understanding its limits. For readers, the practical point is to discuss genetic findings and screening choices with qualified clinicians rather than treating a risk result as a forecast of an individual future.
genetic testing kit for Alzheimer's risk
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Two Notifications in the Account
Carr’s first notification was a genetic report received two years before the Being Patient article was published. He says it identified two APOE4 copies. He describes initially interpreting everyday forgetfulness through that result, then turning to research and prevention information from sources including the USC Center for Personalized Brain Health and Being Patient.
The second notification came after his clinician arranged coronary calcium imaging. Carr writes that his father had a heart attack at 65, and that he himself was also 65 when the scan identified coronary plaque. He contrasts his father’s first indication of heart disease—a heart attack—with his own scan finding. The supplied source excerpt ends during his account of discussing the experience with people close to him, before explaining the third notification.
“APOE4 is not a diagnosis. It is a risk factor.”
— Ron Carr, in Being Patient
As an affiliate, we earn on qualifying purchases.
The Third Notification Is Missing
The source material provided here does not identify the third health notification named in the headline, nor does it include the article’s full conclusion. It therefore cannot establish how that notification fits into Carr’s account. The excerpt also does not provide the scan’s numerical calcium score, detailed laboratory results, medication names or doses, or the clinician’s full explanation of the treatment plan.
Carr’s report is a first-person account, not a clinical study. It does not show how common his experience is or establish that APOE4 testing should lead to coronary calcium scans for other people. The article excerpt cites a Lancet Commission estimate that up to 45% of dementia cases may be attributable to potentially modifiable risk factors, but it does not provide the underlying study details here. That estimate should not be read as a prediction of an individual’s risk or as proof that a particular intervention prevents dementia.
As an affiliate, we earn on qualifying purchases.
Clinical Decisions Remain Individual
Carr says his clinician responded to the scan by seeking lower LDL cholesterol and ApoB levels, and that later testing showed no structural heart damage. The source excerpt does not specify his subsequent test schedule or report further outcomes. It also does not describe what happened after the third notification.
For readers considering genetic testing or cardiovascular screening, the account points to questions for a clinician: what a result can and cannot tell them, whether additional testing is appropriate given their own health history, and what the benefits and drawbacks of possible interventions may be. Any decisions about testing, medication or diet should be made with a qualified health professional familiar with the individual’s circumstances.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did Carr learn from his genetic test?
He writes that testing showed two copies of APOE4, a genetic risk factor associated with late-onset Alzheimer’s disease. He emphasizes that a risk factor is not itself an Alzheimer’s diagnosis.
What did the coronary scan show?
Carr says the scan showed significant calcified plaque in his coronary arteries, with most of it concentrated in the left anterior descending artery. The supplied account does not give a numerical scan score.
Does Carr’s account show that APOE4 causes heart disease?
No. Carr reports that his clinician discussed APOE4’s role in lipid transport and that his scan found plaque. This personal account does not establish that APOE4 caused his plaque or prove a general causal relationship.
What was the third health notification?
The supplied source excerpt does not say. It details the genetic result and heart scan, but stops before identifying the third notification or giving the full article ending.
Does an APOE4 result mean someone will develop Alzheimer’s?
No. Carr’s account distinguishes a genetic risk factor from a diagnosis. A personal result should be discussed with a qualified clinician, who can explain its meaning and limits in light of an individual’s health history.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
